Heart Failure

2. This class of medications are used in HF patients with persistent volume overload
4. Refractory HF requiring specialized interventions
6. Sacubitril/valsartan fall under this medication class
8. Guidelines currently recommend empagliflozin and this other SGLT2 inhibitor for treatment of NYHA class II-IV HF
11. This type of imaging allows for assessment of various cardiac parameters including LVEF
13. At high risk for HF but without structural heart disease or symptoms of HF
14. Structural heart disease with prior or current symptoms of HF
15. This medication is used for persistently symptomatic Black patients
16. Out-of-pocket cost, difficult access to pharmacy, lack of social support, homelessness are all examples of this type of barrier to medication adherence
17. This is one of the most studied biomarkers in HF used for diagnosis and prognosis

1. African-Americans may be at a higher risk of this adverse effect of ACE inhibitors, ARBs and ARNIs
3. This study showed superiority in sacubitril/valsartan compared to enalapril in reducing rates of CV death or HF hospitalization in NYHA class II-IV patients
5. This medication has a target dose of 25 mg twice daily for weight <85 kg and 50 mg twice daily for weight greater than or equal to 85 kg
7. Structural heart disease but without signs or symptoms of HF
9. This salt form of metoprolol is preferred in heart failure patients
10. Clinical diagnosis of HF and LVEF less than or equal to 40%
12. This medication is used in patients with a resting HR greater than or equal to 70 on a maximally tolerated beta-blocker in sinus rhythm
13. This medication is not recommended in patients with a potassium level >5 mEq/L